3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Multiple Endocrine Neoplasia Type 2a
1
Malignant Solid Tumor
1
Lymphoma
1
Lethal Congenital Contracture Syndrome 2
1
Hematologic Neoplasms
1
Fallopian Tube Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Advanced Solid Tumor Malignancies
1
Advanced Solid Tumor
1
Interventions
Ipilimumab
9
pembrolizumab
6
Nivolumab
4
tremelimumab
3
Paclitaxel
3
Carboplatin
3
spartalizumab
2
lenvatinib
2
durvalumab
2
Doxorubicin
2
Bevacizumab
2
trastuzumab deruxtecan
1
tilsotolimod
1
tebentafusp
1
osimertinib
1
eribulin
1
envafolimab
1
cemiplimab
1
balstilimab
1
Vemurafenib
1
Vascular Endothelial Growth Factor A
1
Standard of Care
1
Pemetrexed
1
Oxaliplatin
1
Docetaxel
1
Cisplatin
1
Capecitabine
1
Axitinib
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Diabetes Mellitus, Insulin-Dependent, 12
×
Antibodies, Bispecific
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled